1. Home
  2. BMI vs IONS Comparison

BMI vs IONS Comparison

Compare BMI & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMI
  • IONS
  • Stock Information
  • Founded
  • BMI 1905
  • IONS 1989
  • Country
  • BMI United States
  • IONS United States
  • Employees
  • BMI N/A
  • IONS N/A
  • Industry
  • BMI Industrial Machinery/Components
  • IONS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BMI Industrials
  • IONS Health Care
  • Exchange
  • BMI Nasdaq
  • IONS Nasdaq
  • Market Cap
  • BMI 7.2B
  • IONS 6.6B
  • IPO Year
  • BMI N/A
  • IONS 1991
  • Fundamental
  • Price
  • BMI $188.86
  • IONS $40.84
  • Analyst Decision
  • BMI Buy
  • IONS Buy
  • Analyst Count
  • BMI 7
  • IONS 14
  • Target Price
  • BMI $239.33
  • IONS $57.79
  • AVG Volume (30 Days)
  • BMI 514.7K
  • IONS 1.9M
  • Earning Date
  • BMI 07-22-2025
  • IONS 07-30-2025
  • Dividend Yield
  • BMI 0.72%
  • IONS N/A
  • EPS Growth
  • BMI 19.85
  • IONS N/A
  • EPS
  • BMI 4.59
  • IONS N/A
  • Revenue
  • BMI $873,926,000.00
  • IONS $944,050,000.00
  • Revenue This Year
  • BMI $13.14
  • IONS $9.21
  • Revenue Next Year
  • BMI $8.86
  • IONS $14.35
  • P/E Ratio
  • BMI $41.14
  • IONS N/A
  • Revenue Growth
  • BMI 11.82
  • IONS 16.05
  • 52 Week Low
  • BMI $162.17
  • IONS $23.95
  • 52 Week High
  • BMI $256.08
  • IONS $50.43
  • Technical
  • Relative Strength Index (RSI)
  • BMI 31.52
  • IONS 47.04
  • Support Level
  • BMI $182.66
  • IONS $40.03
  • Resistance Level
  • BMI $190.95
  • IONS $43.74
  • Average True Range (ATR)
  • BMI 6.10
  • IONS 1.37
  • MACD
  • BMI 0.22
  • IONS -0.38
  • Stochastic Oscillator
  • BMI 31.22
  • IONS 14.39

About BMI Badger Meter Inc.

Badger Meter Inc is an innovator, manufacturer, and marketer of products incorporating flow measurement, quality, control, and other system solutions serving markets. The company's products measure water, oil, chemicals, and other fluids, and provide and communicate timely measurement data. Its product lines include two categories: sales of water meters, radios, software, and related technologies, and water quality monitoring solutions to water utilities (utility water) and sales of meters and other sensing instruments, valves, software, and other solutions for industrial applications in water, wastewater, and other industries (flow instrumentation). It derives a majority of its revenues from the United States.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Share on Social Networks: